Table 5 Activities to viruses in relapsing-remitting multiple sclerosis prospective samples by duration between serum collection and symptom onset

AntibodyCategoriesArbitrary units≥5 y<5 y
≥5 y<5 yOR95% CIOR95% CI
ORs and 95% CIs estimated in multivariate logistic regression analysis.
EBV-EBNA-1Low<126<12711
Medium126–140127–1430.680.20–2.30.980.16–5.8
High>140>1434.21.2–14111.5–75
EBV-VCALow11
Medium0.540.19–1.50.370.078–1.7
High1.40.40–5.10.160.032–0.86
HSVLow<72<7311
Medium72–12773–1201.00.38–2.72.60.52–13
High>127>1210.360.11–1.20.950.22–4.1
VZVLow<50<4611
Medium50–7246–671.50.53–4.30.390.083–1.8
High>72>670.400.12–1.41.30.34–5.3
MeaslesLow<125<12211
Medium125–153122–1471.20.36–4.00.520.10–2.5
High>153>1471.70.44–6.60.750.12–4.6
HHV-6Low<51<4711
Medium51–7547–661.90.60–6.05.70.80–41
High>75>662.50.78–8.2121.8–76
No of cases
    Total3926
    Females3823
    Males13
Median age, y (range)26 (17–59)27 (21–49)